

Takeda Pharmaceutical (TAK) beats Q2 estimates and lifts fiscal 2026 guidance as pipeline growth and cost cuts balance off-patent Vyvanse losses.
You can purchase shares of Takeda Pharmaceutical Co (NYSE:TAK) through any online brokerage.
Other companies in Takeda Pharmaceutical Co’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
There is no analysis for Takeda Pharmaceutical Co to provide a consensus price target.
The stock price for Takeda Pharmaceutical Co (NYSE: TAK) is $20.985 last updated November 4, 2026 at 1:59 PM EST.
There are no upcoming dividends for Takeda Pharmaceutical Co.
Takeda Pharmaceutical Co does not have any upcoming earnings scheduled.
There is no upcoming split for Takeda Pharmaceutical Co.
Takeda Pharmaceutical Co is in the Health Care sector and Pharmaceuticals industry. They are listed on the NYSE.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies,...